Entasis Therapeutics Holdings Inc.
ETTX
ETTX was delisted on the 8th of July, 2022.
22 hedge funds and large institutions have $5.77M invested in Entasis Therapeutics Holdings Inc. in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 10 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% less capital invested
Capital invested by funds: $7.24M → $5.77M (-$1.46M)
21% less funds holding
Funds holding: 28 → 22 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GF
Gabelli Funds
Rye,
New York
|
+$108K |
| 2 |
DMKJ
David M. Knott Jr
|
+$75.9K |
| 3 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$74.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$369K |
| 2 |
Two Sigma Investments
New York
|
-$218K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$120K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$87.3K |
| 5 |
VF
Virtu Financial
New York
|
-$53K |
ETTX Hedge Fund Activity: Q1 2022 in Review
22 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Entasis Therapeutics Holdings Inc. (ETTX) for Q1 2022, worth a combined $5.77M — down 20% from $7.24M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ETTX and 4 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Gabelli Funds, opening a new position worth an estimated $108K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $369K sold.
- 22 institutional investors held Entasis Therapeutics Holdings Inc. (ETTX) as of Q1 2022, down from 28 in Q4 2021.
- Funds reported $5.77M of Entasis Therapeutics Holdings Inc. stock for Q1 2022, down 20% quarter-over-quarter.
- 4 funds opened new Entasis Therapeutics Holdings Inc. positions in Q1 2022 and 10 closed out, a net change of -6 holders.
- The largest Entasis Therapeutics Holdings Inc. buyer in Q1 2022 was Gabelli Funds, an estimated $108K added.
- The largest Entasis Therapeutics Holdings Inc. seller in Q1 2022 was Two Sigma Advisers, an estimated $369K sold.
Based on aggregated 13F filings for Q1 2022.